BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

250 related articles for article (PubMed ID: 25630839)

  • 1. MicroRNA let-7a modifies the effect of self-renewal gene HIWI on patient survival of epithelial ovarian cancer.
    Lu L; Katsaros D; Risch HA; Canuto EM; Biglia N; Yu H
    Mol Carcinog; 2016 Apr; 55(4):357-65. PubMed ID: 25630839
    [TBL] [Abstract][Full Text] [Related]  

  • 2. LIN-28B/let-7a/IGF-II axis molecular subtypes are associated with epithelial ovarian cancer prognosis.
    Lu L; Katsaros D; Canuto EM; Biglia N; Risch HA; Yu H
    Gynecol Oncol; 2016 Apr; 141(1):121-7. PubMed ID: 26751131
    [TBL] [Abstract][Full Text] [Related]  

  • 3. MicroRNA let-7a: a potential marker for selection of paclitaxel in ovarian cancer management.
    Lu L; Schwartz P; Scarampi L; Rutherford T; Canuto EM; Yu H; Katsaros D
    Gynecol Oncol; 2011 Aug; 122(2):366-71. PubMed ID: 21571355
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hypermethylation of let-7a-3 in epithelial ovarian cancer is associated with low insulin-like growth factor-II expression and favorable prognosis.
    Lu L; Katsaros D; de la Longrais IA; Sochirca O; Yu H
    Cancer Res; 2007 Nov; 67(21):10117-22. PubMed ID: 17974952
    [TBL] [Abstract][Full Text] [Related]  

  • 5. miRNA-200a/c as potential biomarker in epithelial ovarian cancer (EOC): evidence based on miRNA meta-signature and clinical investigations.
    Teng Y; Su X; Zhang X; Zhang Y; Li C; Niu W; Liu C; Qu K
    Oncotarget; 2016 Dec; 7(49):81621-81633. PubMed ID: 27835595
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinicopathological values of NBS1 and DNA damage response genes in epithelial ovarian cancers.
    Lee YK; Park NH; Lee H
    Exp Mol Med; 2015 Nov; 47(11):e195. PubMed ID: 26584681
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Upregulation of centrosomal protein 55 is associated with unfavorable prognosis and tumor invasion in epithelial ovarian carcinoma.
    Zhang W; Niu C; He W; Hou T; Sun X; Xu L; Zhang Y
    Tumour Biol; 2016 May; 37(5):6239-54. PubMed ID: 26615423
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Differential MicroRNA Expression Profiles in Primary and Recurrent Epithelial Ovarian Cancer.
    Chong GO; Jeon HS; Han HS; Son JW; Lee YH; Hong DG; Lee YS; Cho YL
    Anticancer Res; 2015 May; 35(5):2611-7. PubMed ID: 25964536
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Overexpression of piRNA pathway genes in epithelial ovarian cancer.
    Lim SL; Ricciardelli C; Oehler MK; Tan IM; Russell D; Grützner F
    PLoS One; 2014; 9(6):e99687. PubMed ID: 24932571
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Let-7e sensitizes epithelial ovarian cancer to cisplatin through repressing DNA double strand break repair.
    Xiao M; Cai J; Cai L; Jia J; Xie L; Zhu Y; Huang B; Jin D; Wang Z
    J Ovarian Res; 2017 Apr; 10(1):24. PubMed ID: 28376831
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Increased expression of protein kinase CK2α correlates with poor patient prognosis in epithelial ovarian cancer.
    Ma Z; Wang X; He J; Xia J; Li Y
    PLoS One; 2017; 12(3):e0174037. PubMed ID: 28355289
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Down-regulated miR-22 as predictive biomarkers for prognosis of epithelial ovarian cancer.
    Wan WN; Zhang YQ; Wang XM; Liu YJ; Zhang YX; Que YH; Zhao WJ; Li P
    Diagn Pathol; 2014 Sep; 9():178. PubMed ID: 25257702
    [TBL] [Abstract][Full Text] [Related]  

  • 13. FOXM1 expression is significantly associated with chemotherapy resistance and adverse prognosis in non-serous epithelial ovarian cancer patients.
    Tassi RA; Todeschini P; Siegel ER; Calza S; Cappella P; Ardighieri L; Cadei M; Bugatti M; Romani C; Bandiera E; Zanotti L; Tassone L; Guarino D; Santonocito C; Capoluongo ED; Beltrame L; Erba E; Marchini S; D'Incalci M; Donzelli C; Santin AD; Pecorelli S; Sartori E; Bignotti E; Odicino F; Ravaggi A
    J Exp Clin Cancer Res; 2017 May; 36(1):63. PubMed ID: 28482906
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mir-595 is a significant indicator of poor patient prognosis in epithelial ovarian cancer.
    Zhou QH; Zhao YM; Jia LL; Zhang Y
    Eur Rev Med Pharmacol Sci; 2017 Oct; 21(19):4278-4282. PubMed ID: 29077170
    [TBL] [Abstract][Full Text] [Related]  

  • 15. MiR-135a functions as a tumor suppressor in epithelial ovarian cancer and regulates HOXA10 expression.
    Tang W; Jiang Y; Mu X; Xu L; Cheng W; Wang X
    Cell Signal; 2014 Jul; 26(7):1420-6. PubMed ID: 24607788
    [TBL] [Abstract][Full Text] [Related]  

  • 16. MicroRNA-25 expression level is an independent prognostic factor in epithelial ovarian cancer.
    Wang X; Meng X; Li H; Liu W; Shen S; Gao Z
    Clin Transl Oncol; 2014 Nov; 16(11):954-8. PubMed ID: 24696291
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Serum microRNA-92 expression in patients with ovarian epithelial carcinoma.
    Guo F; Tian J; Lin Y; Jin Y; Wang L; Cui M
    J Int Med Res; 2013 Oct; 41(5):1456-61. PubMed ID: 23963852
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Long non-coding RNA CPS1-IT1 is a positive prognostic factor and inhibits epithelial ovarian cancer tumorigenesis.
    Wang YS; Ma LN; Sun JX; Liu N; Wang H
    Eur Rev Med Pharmacol Sci; 2017 Jul; 21(14):3169-3175. PubMed ID: 28770969
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Over-Expression of TBL1XR1 Indicates Poor Prognosis of Serous Epithelial Ovarian Cancer.
    Ma M; Yu N
    Tohoku J Exp Med; 2017 Mar; 241(3):239-247. PubMed ID: 28344213
    [TBL] [Abstract][Full Text] [Related]  

  • 20. MicroRNA-145 targets TRIM2 and exerts tumor-suppressing functions in epithelial ovarian cancer.
    Chen X; Dong C; Law PT; Chan MT; Su Z; Wang S; Wu WK; Xu H
    Gynecol Oncol; 2015 Dec; 139(3):513-9. PubMed ID: 26472353
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.